SPRB

Spruce Biosciences Inc

53.05

Sep 18 • 3:59 PM ET -0.81 (-1.50%)

53.05

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Micro NASD

Peers: ANTX BDTX TNYA MOLN HURA MENS MSLE OKUR ORMP PLX

| Held by: VTI IWM VXF IWN VTWO IWC IWO DFAS QQQS DFMC

Scroll to Statements

Index	RUT
Market Cap	152.46M
Enterprise Value	63.83M
Income	-51.35M
Sales	0.00M
Book/sh	30.42
Cash/sh	33.51
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	8
IPO	Oct 09, 2020

P/E	-
Forward P/E	59.16
PEG	1.43
P/S	-
P/B	1.74
P/C	1.58
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	9.23
Current Ratio	9.23
Debt/Eq	0.09
LT Debt/Eq	0.06
Option/Short	No / Yes

EPS (ttm)	-40.87
EPS next Y	0.90
EPS next Q	-5.68
EPS this Y	49.35%
EPS next Y	103.48%
EPS next 5Y	41.25%
EPS past 3/5Y	29.85% 11.80%
Sales past 3/5Y	- -
EPS Y/Y TTM	52.43%
Sales Y/Y TTM	-100.00%
EPS Q/Q	-90.92%
Sales Q/Q	-
Earnings	Aug 12 BMO
EPS/Sales Surpr.	-15.37% -

Insider Own	12.62%
Insider Trans	0.00%
Inst Own	66.82%
Inst Trans	40.28%
ROA	-82.38%
ROE	-105.98%
ROIC	-57.98%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-7.34%
SMA50	4.46%
SMA200	-13.64%
Trades

Shs Outstand	2.75M
Shs Float	2.51M
Short Float	17.54%
Short Ratio	5.44
Short Interest	0.44M
52W High	240.00 -77.90%
52W Low	7.26 630.72%
Volatility	6.23% 6.50%
ATR (14)	3.33
RSI (14)	46.42
Beta	3.29
Rel Volume	1.23
Avg Volume	80.94K
Volume	99,677

Perf Week	-1.21%
Perf Month	0.17%
Perf Quarter	1.32%
Perf Half Y	-10.15%
Perf YTD	-39.10%
Perf Year	497.24%
Perf 3Y	-70.77%
Perf 5Y	-90.04%
Perf 10Y	-
Recom	1.00
Target Price	148.00
Prev Close	53.86
Price	53.05
Change %	-1.50%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-17-26	Initiated	Lake Street	Buy	$149
Jul-13-26	Initiated	B. Riley Securities	Buy	$160
Jun-16-26	Initiated	Guggenheim	Buy	$123
Apr-27-26	Initiated	Craig Hallum	Buy	$140
Dec-23-25	Initiated	Oppenheimer	Outperform	$283
Dec-03-25	Upgrade	Leerink Partners	Market Perform → Outperform	$160
Oct-28-25	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform	$254

Sep-08-26 04:05PM	Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference (Business Wire) -5.67%
Aug-27-26 08:09AM	Spruce Biosciences stock gains after analyst backs regulatory progress (InvestorsHub)
Aug-26-26 08:00AM	Spruce Biosciences Announces Launch of MPS3BStudy.com (Business Wire)
Aug-24-26 08:00AM	Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026 (Business Wire) +13.71%
Aug-12-26 09:00AM	Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates (Business Wire)
08:00AM	Loading…
08:00AM	Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences (Business Wire)
Aug-03-26 08:00AM	Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development (Business Wire)
Jul-27-26 08:00AM	Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer (Business Wire)
Jul-13-26 09:41AM	American Express, Biogen upgraded: Wall Street's top analyst calls (The Fly)
Jul-08-26 04:01PM	Spruce Biosciences to Participate in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit (Business Wire)
Jun-29-26 08:00AM	Spruce Biosciences Joins the Russell 3000 Index (Business Wire)
Jun-22-26 08:00AM	Spruce Biosciences Appoints Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President, Medical Affairs (Business Wire)
Jun-15-26 08:00AM	Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller (Business Wire)
Jun-09-26 09:32AM	Toll Brothers upgraded, Lennar downgraded: Wall Street's top analyst calls (The Fly)
Jun-08-26 04:05PM	Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium (Business Wire)
04:05PM	Loading…
May-28-26 04:05PM	Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium (Business Wire)
May-27-26 04:05PM	Spruce Biosciences to Participate in Upcoming Conferences in June (Business Wire)
May-13-26 08:00AM	Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates (Business Wire)
May-04-26 08:00AM	Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations (Business Wire)
Apr-20-26 11:45PM	Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants (Business Wire) -26.05%
04:01PM	Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (Business Wire)
Apr-03-26 08:00PM	Wall Street Analysts Believe Spruce Biosciences (SPRB) Could Rally 181.21%: Here's is How to Trade (Quartz)
Mar-09-26 07:05AM	Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates (Business Wire) +11.17%
07:00AM	Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer (Business Wire)
Mar-03-26 10:20AM	Spruce Biosciences (SPRB) Gains FDA Support for Accelerated Approval Pathway (Insider Monkey)
Mar-02-26 04:05PM	Spruce Biosciences to Present at Upcoming Investor Conferences in March (Business Wire)
Mar-01-26 05:37PM	Spruce Biosciences Touts MPS IIIB Data, Targets Q4 BLA Submission at Oppenheimer Conference (MarketBeat)
Feb-18-26 07:00AM	Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) (Business Wire) -8.18%
Feb-17-26 04:05PM	Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference (Business Wire) -12.14%
Feb-05-26 04:05PM	Long-Term Data Presented at the 22nd Annual WORLDSymposium Highlights Tralesinidase Alfa Enzyme Replacement Therapys Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB) (Business Wire) -10.58%
08:00AM	Loading…
Feb-03-26 08:00AM	Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team (Business Wire) +7.05%
Jan-28-26 08:00AM	Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium (Business Wire)
Jan-21-26 07:24AM	Big-Pharma Partner Harbour BioMed Boosts Stake In Spruce Biosciences (Benzinga) +10.44%
Jan-18-26 07:02PM	Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration (PR Newswire)
Jan-08-26 08:00AM	Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital (Business Wire) -5.62%
Dec-24-25 06:30AM	Spruce Biosciences initiated with an Outperform at Oppenheimer (TipRanks)
Dec-23-25 09:33AM	Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls (The Fly)
08:13AM	Here Are Tuesdays Top Wall Street Analyst Research Calls: AMETEK, Coty, Janus Henderson, Levi Strauss, Pool Corporation, Southern Copper, and More (24/7 Wall St.)
Dec-15-25 08:00AM	Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors (Business Wire)
Nov-10-25 04:05PM	Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates (Business Wire) -8.97%
Oct-15-25 12:00PM	What Makes Spruce Biosciences, Inc. (SPRB) a Strong Momentum Stock: Buy Now? (Zacks) -10.09%
Oct-08-25 08:00AM	Spruce Biosciences Announces $50.0 Million Private Placement Financing (Business Wire) -12.34%
Oct-07-25 09:44AM	This Biotech Stock Soared 1,400%. Investors Are Optimistic About Its Rare-Disease Drug. (Barrons.com) +40.03%
Oct-06-25 05:04PM	Why Spruce Biosciences Just Skyrocketed Almost 1,400% (Investor's Business Daily) +1,378.46%
08:00AM	Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB) (Business Wire)
Sep-15-25 07:00AM	Spruce Biosciences Resumes Trading on the Nasdaq Capital Market (Business Wire) -20.97%

Spruce Biosciences, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.

MDJavier Szwarcberg

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ways Douglas Kirk	Interim Chief Medical Officer	Dec 11 '25	Option Exercise	0.00	1,250	0	1,250	Jan 21 04:04 PM
Gharib Samir M.	PRESIDENT AND CFO	Dec 15 '25	Option Exercise	0.00	1,009	0	8,447	Dec 17 04:58 PM
Szwarcberg Javier B.	CHIEF EXECUTIVE OFFICER	Dec 15 '25	Option Exercise	0.00	2,676	0	14,922	Dec 17 04:56 PM
Gharib Samir M.	PRESIDENT AND CFO	Dec 11 '25	Option Exercise	0.00	1,900	0	8,296	Dec 12 07:05 PM
Gharib Samir M.	PRESIDENT AND CFO	Dec 10 '25	Option Exercise	0.00	514	0	6,580	Dec 12 07:05 PM
Szwarcberg Javier B.	CHIEF EXECUTIVE OFFICER	Dec 11 '25	Option Exercise	0.00	4,950	0	15,192	Dec 12 07:03 PM
Szwarcberg Javier B.	CHIEF EXECUTIVE OFFICER	Dec 10 '25	Option Exercise	0.00	1,196	0	10,670	Dec 12 07:03 PM
Gharib Samir M.	PRESIDENT AND CFO	Oct 20 '25	Option Exercise	0.00	2,053	0	6,727	Oct 22 04:15 PM
Szwarcberg Javier B.	CHIEF EXECUTIVE OFFICER	Oct 20 '25	Option Exercise	0.00	4,784	0	11,013	Oct 22 04:15 PM
Parkman Healthcare Partners LL	10% Owner	Oct 06 '25	Buy	17.91	256	4,585	1,307	Oct 15 04:32 PM
Parkman Healthcare Partners LL	10% Owner	Oct 06 '25	Sale	19.14	257	4,920	1,050	Oct 15 04:32 PM
Parkman Healthcare Partners LL	10% Owner	Oct 06 '25	Buy	17.91	256	4,585	1,307	Oct 08 08:55 PM
Parkman Healthcare Partners LL	10% Owner	Oct 06 '25	Sale	19.14	257	4,920	1,050	Oct 08 08:55 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SPRB

Spruce Biosciences Inc

Upgrade your Finviz experience